#ObesityMedicine #MetabolicHealth #GLP1 #ClinicalTrials #HealthcareInnovation #Semaglutide #Orforglipron #CagriSema #Retatrutide #Wegovy To view or add a comment, sign in CagriSema Pushes the Limits of Pharmacologic Weight Loss The phase IIIa REDEFINE 1 trial marks an important milestone in obesity treatment
If you are considering either medication as part of a supervised weight loss program, a comprehensive evaluation is the starting point
The 2mg starting dose produces gradual initial progress compared to higher doses
Ensure you understand any exclusions related to weight loss services, off-label use, or compounding
This pharmacologic gastroparesis can unpredictably delay absorption of other orally administered drugs, potentially altering expected toxicokinetics
Such lesions are flat, within the level of the skin, and thus a macule ( Fig